ARA-290, also known as Cibinetide, is an 11-amino acid synthetic peptide derived from the helix B region of erythropoietin (EPO). Unlike EPO itself, ARA-290 selectively activates the innate repair receptor (IRR) — a heterodimer of the EPO receptor and the common beta receptor (βcR) — without engaging the classical erythropoietic receptor complex. This selective binding profile makes ARA-290 of considerable research interest, as it confers tissue-protective and anti-inflammatory effects without the haematopoietic side effects associated with EPO.
In preclinical and early clinical research, ARA-290 has been studied for its potential role in peripheral neuropathy, metabolic disorders including type 2 diabetes, sarcoidosis-associated small fibre neuropathy, and inflammatory conditions. Research suggests it may modulate macrophage polarisation, promote neuronal survival, and support pancreatic beta-cell function.
Each vial contains 10mg of ARA-290 supplied as a lyophilised powder. Molecular formula: C₅₁H₇₉N₁₅O₁₇S. Molecular weight: approximately 1174.3 g/mol. Purity: >98% by HPLC. CAS number: 1234354-98-3. Recommended storage at -20°C, protected from light and moisture, with reconstitution in sterile bacteriostatic water immediately prior to use.
Molecular Formula
C₅₁H₇₉N₁₅O₁₇S
Molecular Weight
1174.3 g/mol
Purity
>98%
CAS Number
1234354-98-3
Form
Lyophilised Powder
Research Applications
Peripheral neuropathy, Neuroprotection, Metabolic disorders and diabetes research, Anti-inflammatory mechanisms, Pancreatic beta-cell function, Tissue repair and cytoprotection
For research purposes only. Not for human use.
Reviews
There are no reviews yet.